Page 2 - ஜய்துச் ஆரோக்கியம் வரையறுக்கப்பட்டவை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஜய்துச் ஆரோக்கியம் வரையறுக்கப்பட்டவை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஜய்துச் ஆரோக்கியம் வரையறுக்கப்பட்டவை Today - Breaking & Trending Today

India to have 51.6 crore Covid vaccine doses by July: Harsh Vardhan


India to have 51.6 crore Covid vaccine doses by July: Harsh Vardhan
SECTIONS
Last Updated: May 15, 2021, 10:20 PM IST
Share
Synopsis
Vardhan, during his discussion with the health ministers of Uttar Pradesh, Gujarat, Madhya Pradesh and Andhra Pradesh, said vaccine production was being ramped up to cater to the increased demand.
AFP
3,353,630.0
The number of vaccine doses administered in India will reach 51.6 crore by the end of July, Union Health Minister Harsh Vardhan said on Saturday. India has so far administered over 18 crore jabs to eligible beneficiaries.
Vardhan, during his discussion with the health ministers of Uttar Pradesh, Gujarat, Madhya Pradesh and Andhra Pradesh, said vaccine production was being ramped up to cater to the increased demand. ....

Madhya Pradesh , Uttar Pradesh , East Godavari , Andhra Pradesh , Harsh Vardhan , Ashwini Kumar Choubey , Sujeetk Singh , Guntur Srikakulam , States Union Territories , Union Health , Union Health Ministry , National Centre For Disease Control , Serum Institute Of India Novavax , Union Health Minister Harsh Vardhan , Serum Institute , Bharat Biotech , Union Minister , Family Welfare , National Centre , Disease Control , Corona Virus , Vaccine Doses , Covid Vaccine , மத்யா பிரதேஷ் , உத்தர் பிரதேஷ் , கிழக்கு கோதாவரி ,

remdesivir: PIL in HC seeks all Remdesivir makers be allowed to sell it in domestic market


Cadila, seeking their stand on the plea which claims only a handful of such firms are allowed to sell the medicine in the domestic market.
The remaining companies were involved in manufacturing the drug for export, petitioner Dincur Bajaj said, adding that since export of Remdesivir has been banned by the Centre, the companies which were producing it for export be permitted to manufacture and sell it in the domestic market.
Bajaj, who is a lawyer and the Joint Secretary of the Delhi High Court Bar Association, has claimed that there are more than 25 companies in India which manufacture the medicine, but only six to eight of them are permitted to sell it in the domestic market and the rest were producing it for exports alone. ....

Imran Ali , Dincur Bajaj , Amit Saxena , Justicedn Patel , Justice Jasmeet Singh , Supreme Court , Delhi High Court Bar Association , Delhi High Court , Health Ministry , Central Drugs Standard Control Organisation , Delhi High Court Monday , Chief Justicedn Patel , Director General , Foreign Trade , Joint Secretary , இம்ரான் அலி , அமித் சகஷெண , நீதி ஜாஸ்மீட் சிங் , உச்ச நீதிமன்றம் , டெல்ஹி உயர் நீதிமன்றம் மதுக்கூடம் சங்கம் , டெல்ஹி உயர் நீதிமன்றம் , ஆரோக்கியம் அமைச்சகம் , மைய மருந்துகள் தரநிலை கட்டுப்பாடு ஆர்கநைஸேஶந் , டெல்ஹி உயர் நீதிமன்றம் திங்கட்கிழமை , இயக்குனர் ஜநரல் , வெளிநாட்டு வர்த்தகம் ,

Zydus Cadila's Virafin granted restricted emergency use approval for treating Covid patients: DBT | India News


NEW DELHI: Drug Controller General Of India (DCGI) has granted restricted emergency use approval to Zydus Cadila s Virafin for treating patients showing moderate Covid-19 symptoms, the department of biotechnology said on Saturday.
Virafin is a pegylated interferon alpha-2b(PegIFN), which when subcutaneously injected to the patient in the early stages of infection, results in their faster recovery, it said.
The studies confirmed the safety, tolerability and efficacy of Virafin. The studies also reported that Viarfin reduces viral load and aid in managing the disease in a better way, such as reduction in the need for supplemental oxygen, thereby reducing the respiratory tension caused due to low oxygen levels, the DBT said. ....

Zydus Cadila , Zydus Cadila Virafin , Renu Swarup , Biotechnology Industry Research Assistance Council , Drug Controller General Of India , Pegylated Interferon , Ndia News , Ndia News Today , Oday News , Google News , Reaking News , ஜய்துச் காடிலா , ரேணு சுவருப் , உயிரி தொழில்நுட்பவியல் தொழில் ஆராய்ச்சி உதவி சபை , மருந்து கட்டுப்படுத்தி ஜநரல் ஆஃப் இந்தியா ,

Zydus' antiviral Virafin receives emergency authorisation for COVID-19 treatment


Zydus antiviral Virafin receives emergency authorisation for COVID-19 treatment
Zydus Cadila stated that 91.15 per cent of patients who were treated with the antiviral Virafin were RT-PCR negative by Day 7. The treatment also reduces hours of supplemental oxygen in patients
BusinessToday.In | April 23, 2021 | Updated 15:35 IST
Zydus Cadila s Virafin receives EUA/Representational image
Zydus Cadila said that its antiviral Virafin has been given emergency use authorisation by the Drug Controller General of India (DCGI) for treatment against coronavirus. The pharma company said that a single dose of the antiviral administered subcutaneously early on shows significant clinical and virological improvement in patients with moderate coronavirus. It stated that 91.15 per cent of patients who were treated with the antiviral were RT-PCR negative by Day 7. The treatment also reduces hours of supplemental oxygen in patients. ....

Zydus Cadila , Sharvil Patel , Drug Controller General , Pegylated Interferon , Managing Director , Cadila Healthcare , Covid Treatment , Antiviral Virafin , Antiviral Drug Virafin , Virafin Drug , Virafin News , Treatment Of Moderate Covid 19 Infections , Treatment Of Covid 19 , Zydus Antiviral Virafin , Treatment Against Coronavirus , Pharma Company , Zydus Pharma , ஜய்துச் காடிலா , ஷார்வில் படேல் , மருந்து கட்டுப்படுத்தி ஜநரல் , நிர்வகித்தல் இயக்குனர் , காடிலா சுகாதாரம் , பார்மா நிறுவனம் , ஜய்துச் பார்மா ,

DGCI approves emergency use of Zydus's Virafin in treating moderate COVID-19 infection


DGCI approves emergency use of Zydus s Virafin in treating moderate COVID-19 infection
ANI |
Updated: Apr 23, 2021 16:36 IST
By Joymala Bagchi
New Delhi [India], April 23 (ANI): Zydus Cadila received emergency use approval from the Drugs Controller General of India (DGCI) on Friday for the use of Virafin , Pegylated Interferon alpha-2b (PegIFN) in treating moderate COVID-19 infection in adults.
A single-dose subcutaneous regimen of the antiviral Virafin will make the treatment more convenient for the patients. When administered early on during COVID-19, Virafin will help patients recover faster and avoid much of the complications, the company said.
In a release, Cadila Health highlighted that the drug has also shown efficacy against other viral infections. ....

New Delhi , Joymala Bagchi , Zydus Cadila , Sharvil Patel , Cadila Health , Cadila Healthcare , Drugs Controller General , Pegylated Interferon , Managing Director , Cadila Healthcare Limited , Emergency Use Approval , புதியது டெல்ஹி , ஜய்துச் காடிலா , ஷார்வில் படேல் , காடிலா ஆரோக்கியம் , காடிலா சுகாதாரம் , மருந்துகள் கட்டுப்படுத்தி ஜநரல் , நிர்வகித்தல் இயக்குனர் , காடிலா சுகாதாரம் வரையறுக்கப்பட்டவை ,